Separately, X4 Pharmaceuticals announced positive new clinical data from now completed Phase 2 clinical trial evaluating mavorixafor in the treatment of people with chronic neutropenia. An analysis of ...
SER-155 Phase 1b placebo-controlled clinical results demonstrated significant reduction in both bacterial bloodstream infections and systemic antibiotic exposure, as well as lower incidence of febrile ...